is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting, following its promising survival ...

is pleased to announce that the Company will be presenting a poster at the upcoming European Society for Medical Oncology's ("ESMO”) Breast Cancer meeting, following its promising survival ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the most effective dose, above the 5% threshold deemed clinically ...

The data was still under wraps at that time, but has just been revealed in the ESMO congress abstract drop – a 3.2 month improvement over control, compared to 1.6 months at ASCO. Taken in ...

It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 ...